GleamWall
中文EN

UNCY Unicycive Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1766140 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-8.4%
TTM EPS YoY53.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-80.4%
ROA-60.1%
ROIC (approx.)-1,005.6%
Asset turnover—

Leverage & solvency

Liabilities / assets24.8%
Debt / equity0.00x
Current ratio4.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-11.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$2.25M$2.79M$1.61M$2.25M$2.96M$1.75M$2.17M$5.29M
SG&A expense$6.59M$7.35M$6.83M$4.97M$4.38M$5.21M$5.82M$3.97M
Operating income-$8.84M-$10.14M-$8.44M-$7.22M-$7.34M-$6.96M-$7.99M-$9.26M
Interest expense———$27,000$15,000$13,000$15,000$20,000
Net income-$7.00M-$1.72M-$12.82M-$14.67M-$6.01M-$6.45M$570,000-$21.52M
EBITDA-$8.83M-$10.13M-$8.43M-$7.21M-$7.33M-$6.96M-$7.98M-$9.25M
EPS (basic)-0.25-0.06-0.54—-0.33-0.520.04—
EPS (diluted)-0.25-0.06-0.54—-0.33-0.52-0.50—
Weighted avg. shares (diluted)28.27M26.92M23.91M—18.07M12.30M12.38M—
Balance sheet
Cash & equivalents$41.97M$44.19M$37.37M$29.20M$42.70M$22.33M$19.77M$26.14M
Short-term investments$17.01M$17.24M$17.21M$12.07M————
Current assets$69.16M$71.32M$63.55M$48.96M$50.29M$29.53M$27.35M$30.95M
PP&E, net$255,000$41,000$48,000$66,000$75,000$83,000$83,000$75,000
Total assets$69.93M$72.03M$64.41M$49.13M$50.61M$30.00M$27.95M$31.67M
Current liabilities$17.31M$18.70M$26.48M$18.94M$13.13M$13.57M$16.68M$24.12M
Total liabilities$17.31M$18.76M$26.70M$18.94M$13.13M$13.57M$16.68M$24.24M
Shareholders' equity$52.62M$53.27M$37.70M$30.20M$37.48M$16.43M$11.27M$7.43M
Shares outstanding29.11M27.86M25.24M22.11M20.85M14.11M119.75M11.38M
Cash flow statement
Operating cash flow-$7.25M-$7.60M-$6.24M-$8.03M-$5.96M-$8.42M-$8.90M-$6.55M
Capital expenditure$221,000-$1,000$8,000$0$2,000$6,000$16,000$22,000
Free cash flow-$7.47M-$7.60M-$6.25M-$8.03M-$5.96M-$8.43M-$8.92M-$6.57M
Investing cash flow$63,000-$23,000-$5.16M-$12.07M-$2,000-$6,000-$16,000-$22,000
Financing cash flow$4.97M$14.44M$19.57M$6.61M$26.33M$10.98M$2.55M$365,000
Depreciation & amortization$7,000$6,000$8,000$10,000$10,000$6,000$8,000$7,000
Stock-based compensation$1.80M$2.88M$754,000$777,000$729,000$571,000$563,000$582,000
Dividends paid———————$0

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.